Cannabinoids And Other Pain Relief Options
ACCESSWIRE - Mon Nov 12, 11:35AM CST
HENDERSON, NV / ACCESSWIRE / November 12, 2018 / Opioids are a scourge companies across several sectors are looking to help eradicate. Pain relief options are popping up left and right in an attempt to replace the opioids doctors have been prescribing for years. Below are several companies that could be the solution to this major problem
The first on our list is Endonovo Therapeutics, Inc. (ENDV). ENDV has an extremely promising non-invasive pain reduction treatment therapy called SofPulse that could be the answer for larger companies looking at opioid alternative pain relief solutions.
ENDV recently concluded a study on SofPulse's effectiveness in treating nonalcoholic steatohepatitis (NASH). One to 2 weeks of treatment with SofPulse appeared to counteract several of the disease signs associated with NASH-associated liver damage.
Male mice, 8 weeks old were placed on an MCD diet (methionine-choline deficient diet) for either 7 or 14 days. Feeding mice a diet deficient in methionine and choline is a commonly used mouse model to study the inflammation and hepatic ballooning associated with NASH. To determine if Endonovo's non-invasive medical device could ameliorate the manifestations of a NASH induced diet, mice were exposed to either a proprietary electroceutical therapy system or a sham system during the duration of the MCD diet.
ENDV would be a great place to start if you're looking to research potential companies that could be the answer to the opioid crisis.
Companies to put on your radar include: Endonovo Therapeutics, Inc. (ENDV), Aurora Cannabis (NYSE:ACB), Aphria, Inc. (NYSE:APHA), INSYS Therapeutics, Inc. (NASDAQ:INSY), and CV Sciences, Inc. (CVSI).
Endonovo Therapeutics, Inc. (ENDV)
Market Cap: $14.14M Share Price: $0.038
Endonovo Therapeutics, Inc. (ENDV), a commercial-stage developer of Electroceutical™ Therapies, announced a distribution agreement with Magniant, LLC for the distribution of Sofpulse, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.
Alan Collier, Endonovo Chief Executive Officer, stated, "We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our SofPulse device on a national level."
Aurora Cannabis, Inc. (NYSE:ACB)
Market Cap: $7.19B Share Price: $7.49
Aurora Cannabis Inc. (ACB), just announced the official opening of its latest high-tech cannabis production facility in Lachute, Quebec; the company is calling it "Eau."
At 48,000 square feet, with 11 purpose-built grow rooms, Aurora Eau will produce up to 4,500 kg of high quality cannabis per year, all in a facility with some of the lowest electricity costs in North America. It is designed to grow niche varieties of cannabis for the premium medical and adult consumer use markets in Quebec, Canada and around the world. Eau becomes Aurora's second production facility in Quebec , the first being Aurora Vie, a 40,000 square foot indoor grow facility in Pointe Claire, Quebec .
Aphria, Inc. (NYSE:APHA)
Market Cap: $3.29B Share Price: $12.72
Aphria Inc. (APHA) announced an agreement with Rapid Dose Therapeutics Inc. that grants the Company with exclusive global preferred rights to license, manufacture, distribute and sell RDT's QuickStrip™ innovative, proprietary delivery technology for both medical and adult-use cannabis market.
INSYS Therapeutics, Inc. (NASDAQ:INSY)
Market Cap: $605.09M Share Price: $8.15
NSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, recently reported financial results for its third quarter ended Sept. 30, 2018. The company achieved net revenue of $18.3 million in the third quarter of 2018.
CV Sciences, Inc. (CVSI)
Market Cap: $608.87M Share Price: $6.37
CVSI announced that it will be a Title Sponsor of the 25th anniversary of HIACON Conference on November 2-5, in Los Angeles, California. Produced by the Hemp Industries Association (HIA), HIACON will bring together over 400 attendees (cultivators, stakeholders, buyers), more than 55 speakers and industry thought leaders, and many other hemp and CBD sponsors to the Hilton Los Angeles Airport Hotel.
